MedPharm (Tergus Pharma)
Guildford UK, Durham NC
Program data pending ClinicalTrials.gov matching
· Last scored 2026-07-23
80.8
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: MedPharm (Tergus Pharma)
- Signal Score
- 80.8/100 (as of 2026-07-23)
- Quality Compliance
- 100.0/100
- Headquarters
- Guildford UK, Durham NC
- Founded
- 1999
- Website
- https://www.medpharm.com/
- Modalities
- Topical CDMO, Topical Drug Product Development, Transepithelial Drug Delivery, Formulation Development, Analytical Method Development, Analytical Testing, IVRT, IVPT, Human-Relevant In Vitro Models, Semisolid GMP Manufacturing, GMP Clinical Trial Material Manufacturing, GMP Commercial Manufacturing, Stability Studies, Transdermal Drug Delivery, Nasal Drug Delivery, Respiratory Drug Delivery, Ocular Drug Delivery, Nail Drug Delivery, Creams, Gels, Ointments, Lotions
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About MedPharm (Tergus Pharma)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2024-08-30)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesTopical CDMO, Topical Drug Product Development, Transepithelial Drug Delivery, Formulation Development, Analytical Method Development, Analytical Testing, IVRT, IVPT, Human-Relevant In Vitro Models, Semisolid GMP Manufacturing, GMP Clinical Trial Material Manufacturing, GMP Commercial Manufacturing, Stability Studies, Transdermal Drug Delivery, Nasal Drug Delivery, Respiratory Drug Delivery, Ocular Drug Delivery, Nail Drug Delivery, Creams, Gels, Ointments, Lotions
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
68.0
2 manufacturing sites
Broad modality coverage (22 modalities)
Sites: Durham, North Carolina, Guildford, United Kingdom
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
StatusAvailable
2 manufacturing sites
Broad modality coverage (22 modalities)
Sites: Durham, North Carolina, Guildford, United Kingdom
Recent Press10 articles
2 manufacturing sites
Broad modality coverage (22 modalities)
MedPharm (Tergus Pharma) FDA Inspection History
2024-08
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2024-08-30 | Durham, North Carolina | Bioresearch Monitoring | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Aug 22, 2026
Recent News 10 articles
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Durham CDMOs merge backed by private equity - The Business Journals
Performance Cell picked up by private equity firm, rebrands as Cellipont Bioservices - Fierce Pharma
Private Equity Healthcare Acquisitions – July 2024 - Private Equity Stakeholder Project PESP
Prominent CDMO Tergus Pharma Officially Opens New Headquarters - PRWeb
Investment firm Great Point Partners scoops up German CDMO Lyocontract - Fierce Pharma
Tergus Pharma merges with fellow dermatology CDMO MedPharm - Fierce Pharma
Tergus Pharma to become full-fledged CDMO with new manufacturing facility - Fierce Pharma
MedPharm, Ltd. and Tergus Pharma Merger Forms Topical and Transdermal CDMO Leader - PR Newswire
Medpharm Announces Merger with Tergus Pharma - Contract Pharma
Frequently Asked Questions About MedPharm (Tergus Pharma)
How many FDA inspections does MedPharm (Tergus Pharma) have on record?
CDMO Signal tracks 1 FDA inspection for MedPharm (Tergus Pharma), sourced from the FDA inspection database. See the full inspection history above.
Has MedPharm (Tergus Pharma) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for MedPharm (Tergus Pharma).
What is MedPharm (Tergus Pharma)'s CDMO Signal Score?
MedPharm (Tergus Pharma) has a Signal Score of 81/100, based on quality, operations, financial stability, and capacity data.
Evaluating MedPharm (Tergus Pharma) for a manufacturing program?
Use the free AI matchmaker to compare MedPharm (Tergus Pharma) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
CPL CDMO (Skin Lab)
Mississauga, ON, Canada
IVRT, IVPT, Topical Drug Product Development, Semisolid Formulation, Transdermal, Bioequivalence Testing
Vici Health Sciences
Groton, CT
IVPT, IVRT, Topical Drug Product Development, Semisolid Formulation, Transdermal, Physicochemical and Rheological Characterization
Alcami
Wilmington, NC
Sterile Fill-Finish, Drug Product (Injectable), Lyophilization, Small Molecule, Analytical Testing, Terminal Sterilization
Pyramid Pharma Services (Pyramid Laboratories, Inc.)
Costa Mesa, CA
Biologics, Sterile Injectables / Aseptic Fill-Finish, Lyophilization, Peptides, Small Molecules, siRNA/Oligonucleotide Injectable, Formulation Development, Analytical & Stability Testing
Serán Bioscience
Bend, OR
Small Molecule (Oral Solid Dose), Spray Dried Dispersion (SDD), Hot Melt Extrusion (HME), Nano-milling / Nanoparticulate, Fluid Bed Processing, Particle Engineering, Pulmonary / Inhaled Particulates, Nasal Drug Delivery, Finished Dose (tablets, capsules, OPCs, powder-in-bottle)